Related Experiment Video
Updated: Sep 5, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Role of Sarcopenia in Advanced Malignant Cutaneous Melanoma Treated with Immunotherapy: A Meta-Analysis
Alexey Surov1, Hans-Jonas Meyer2, Andreas Wienke3
1Department of Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany.
Abstract:
The role of sarcopenia in malignant cutaneous melanoma is unclear. The aim of the present meta-analysis was to analyze the prevalence and clinical role of sarcopenia in patients with advanced cutaneous melanoma based on a large cohort. MEDLINE, Cochrane, and SCOPUS databases were checked for relationships between sarcopenia and clinical outcomes in melanoma up to September 2021. Overall, 6 studies including 719 patients met the inclusion criteria. The meta-analysis was performed using RevMan 5.3 software. The prevalence of sarcopenia was 40.23%. Sarcopenia did not influence dose-limiting toxicity of treatment, hazard ratio (HR) 1.01, 95% CI (0.70-1.47). Sarcopenia was associated with lower progression-free survival (PFS): HR 1.49, 95% CI (0.98-2.26), and lower overall survival (OS): HR 1.67, 95% CI (1.11-2.52). The cumulative prevalence of sarcopenia in malignant cutaneous melanoma is 40.77%. Sarcopenia is slightly associated with PFS and OS and it is not associated with treatment toxicity.
More Related Videos
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Tumor Microenvironment